Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus U CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus U CORT.
CORTAN vs U-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
U-CORT (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory, immunosuppressive, and metabolic effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production and immune cell migration.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
U-CORT (hydrocortisone) 100 mg intravenous bolus, followed by 100 mg intravenous every 8 hours for 48 hours, then taper as clinically indicated.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal half-life approximately 1.6-2.2 hours; clinically used as short-acting topical corticosteroid.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Primarily hepatic metabolism; inactive metabolites excreted renally (60-70%) and biliary/fecal (20-30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid